Suppr超能文献

血清表面活性剂蛋白 D 或 C 型趋化因子配体 18 能否预测早期系统性硬化症患者间质性肺疾病的预后?

Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?

机构信息

University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.

出版信息

J Rheumatol. 2013 Jul;40(7):1114-20. doi: 10.3899/jrheum.120997. Epub 2013 Apr 15.

Abstract

OBJECTIVE

To examine the predictive significance of 2 pneumoproteins, surfactant protein D (SP-D) and CC-chemokine ligand 18 (CCL18), for the course of systemic sclerosis (SSc)-related interstitial lung disease.

METHODS

The pneumoproteins were determined in the baseline plasma samples of 266 patients with early SSc enrolled in the GENISOS observational cohort. They also were measured in 83 followup patient samples. Pulmonary function tests were obtained annually. The primary outcome was decline in forced vital capacity (FVC percentage predicted) over time. The predictive significance for longterm change in FVC was investigated by a joint analysis of longitudinal measurements (sequentially obtained FVC percentage predicted) and survival data.

RESULTS

SP-D and CCL18 levels were both higher in patients with SSc than in matched controls (p < 0.001 and p = 0.015, respectively). Baseline SP-D levels correlated with lower concomitantly obtained FVC (r = -0.27, p < 0.001), but did not predict the short-term decline in FVC at 1 year followup visit or its longterm decline rate. CCL18 showed a significant correlation with steeper short-term decline in FVC (p = 0.049), but was not a predictor of its longterm decline rate. Similarly, a composite score of SP-D and CCL18 was a significant predictor of short-term decline in FVC but did not predict its longterm decline rate. Further, the longitudinal change in these 2 pneumoproteins did not correlate with the concomitant percentage change in FVC.

CONCLUSION

SP-D correlated with concomitantly obtained FVC, while CCL18 was a predictor of short-term decline in FVC. However, neither SP-D nor CCL18 was a longterm predictor of FVC course in patients with early SSc.

摘要

目的

探讨 2 种肺保护蛋白——表面活性蛋白 D(SP-D)和 CC 趋化因子配体 18(CCL18)——对系统性硬化症(SSc)相关间质性肺病(ILD)病程的预测意义。

方法

在 GENISOS 观察性队列中纳入的 266 例早期 SSc 患者的基线血浆样本中测定了这 2 种肺保护蛋白,同时还测定了 83 例随访患者样本。每年进行肺功能检查。主要结局是用力肺活量(FVC%预计值)随时间的下降。通过对纵向测量值(连续获得的 FVC%预计值)和生存数据的联合分析,研究了 FVC 长期变化的预测意义。

结果

与匹配对照组相比,SSc 患者的 SP-D 和 CCL18 水平均升高(p<0.001 和 p=0.015)。基线 SP-D 水平与同时获得的较低 FVC 相关(r=-0.27,p<0.001),但不能预测 1 年随访时 FVC 的短期下降或其长期下降率。CCL18 与 FVC 的短期下降率呈显著相关性(p=0.049),但不能预测其长期下降率。同样,SP-D 和 CCL18 的复合评分是 FVC 短期下降的显著预测因子,但不能预测其长期下降率。此外,这 2 种肺保护蛋白的纵向变化与同时获得的 FVC 百分比变化无关。

结论

SP-D 与同时获得的 FVC 相关,而 CCL18 是 FVC 短期下降的预测因子。然而,SP-D 和 CCL18 均不能预测早期 SSc 患者的 FVC 病程。

相似文献

引用本文的文献

1
Insights into interstitial lung disease pathogenesis.间质性肺疾病发病机制的见解。
Breathe (Sheff). 2025 May 13;21(2):240261. doi: 10.1183/20734735.0261-2024. eCollection 2025 Apr.
2
The Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease.纤维化间质性肺疾病中精准医学的曙光。
Chest. 2025 Apr;167(4):1120-1132. doi: 10.1016/j.chest.2024.10.042. Epub 2024 Nov 8.
6
Circulating biomarkers of systemic sclerosis - interstitial lung disease.系统性硬化症-间质性肺病的循环生物标志物
J Scleroderma Relat Disord. 2020 Mar;5(2 Suppl):41-47. doi: 10.1177/2397198319894851. Epub 2020 Jan 6.
7
Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?结缔组织病中的支气管肺泡灌洗和肺活检,做还是不做?
Ther Adv Musculoskelet Dis. 2021 Dec 8;13:1759720X211059605. doi: 10.1177/1759720X211059605. eCollection 2021.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验